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Background

Alcohol use disorder (AUD) results in frequent hospital readmissions. Although the literature
has shown the efficacy of anti-craving medications (ACM), they are infrequently prescribed
upon discharge. The outcomes of discharge to substance use treatment facilities (STF) have
also not been fully explored. This study seeks to determine the impact of ACM as well as
discharge to STF on readmissions for people with AUD.

Houston, Texas 77009
(jonbrownjwb@gmail.com)

Methods

This retrospective case-control study analyzed encounters made within HCA Healthcare
hospitals across the United States from 2016 to 2018 for adults with AUD. The case definition was the presence of ACM defined as acamprosate or naltrexone upon discharge as
well as discharge disposition (STF vs. all others). The main outcomes were the likelihood of
30- and 90-day readmission and blood alcohol concentration (BAC) on 30-day readmission
in cases versus adults with AUD declining/not referred to an STF or not using ACM. The
controlled variables included age, sex, race, and insurance status.

Results

A total of 14 691 patients were identified for the study. Of these, 3308 patients were prescribed ACM and 1125 patients were discharged to an STF. Patients without ACM were 1.18
times more likely to be readmitted within 30 days (95% CI, 1.07-1.30; P = .0005). Patients
discharged to an STF were 1.57 times more likely to be readmitted within 30 days (95% CI,
1.37-1.79; P < .0001), but these patients had a BAC that was 26.74 units lower on 30-day readmission than those who were not discharged to an STF.

Conclusion

The prescription of ACM on discharge was associated with decreased 30-day readmission
rates. The lower BAC of those who were readmitted within 30 days suggests discharge to
STF may be beneficial for the treatment of AUD in the longer term. Practitioners are encouraged to prescribe ACM for people admitted with AUD to reduce the likelihood of 30-day
readmission.
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Introduction

Alcohol use disorder (AUD) often results in
hospital readmissions.1 The inpatient setting
provides an opportunity for treating AUD and
initiating anti-craving medication (ACM) upon

discharge. Naltrexone and acamprosate are
medications that are FDA-approved and shown
to be effective in preventing alcohol use relapse.2 A double-blind randomized control trial
with over 6000 subjects showed a decrease
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in the immediate recurrence of alcohol use
relapse in those assigned to acamprosate compared to a placebo.3 Decreased adherence to
ACM is also associated with an earlier relapse
in alcohol consumption.4 Yet less than 9% of
patients with AUD are prescribed medications.5
ACMs for AUD have been shown to decrease
patients’ lengths of stay in hospitals and to
reduce healthcare costs.6 Initiation of a discharge-planning protocol, which included treatment with naltrexone, was associated with a
decrease in 30-day hospital readmission rates
and emergency department visits.1 In another study, treatment for hospitalized trauma
patients with AUD increased cost savings for
hospitals, insurers, and government agencies.7
These cost savings were reflective of a reduction in injuries requiring emergency room treatment or hospitalization. Despite evidence in
the literature, only 7% of substance use disorder (SUD) treatment programs offered acamprosate during its first year of availability in the
United States.8 A prospective study showed
that patients who received pharmacotherapy
for AUD following discharge from residential
AUD programs had a delay in alcohol use, fewer
relapses, and decreased need for inpatient
treatment.9
A retrospective cohort study reported that
AUD-related admissions were associated with
a mortality rate of 11% and accrued over 7 million dollars in cost over a 6-month period.10 The
majority of admitted patients were discharged
home without continuity of care for their
AUD.10 However, transitioning patients to a residential or outpatient SUD treatment program
after discharge has been shown to significantly
reduce readmission rates and associated costs.11
Anti-craving medications affect patients’ alcohol use relapse, but there is a lack of data on
whether ACM have a positive effect on hospital
readmissions. The present retrospective cohort study serves to determine whether there
is an association between the ACM prescribed
as well as disposition on discharge to reduce
30- and 90-day hospital readmission rates as
well as decreased blood alcohol concentration
(BAC) upon 30-day readmission.

Methods

Study Design and Sample

This retrospective study reviewed all existing
40

encounters made within HCA Healthcare
facilities across the United States from January
2016 to December 2018. HCA Healthcare is
comprised of 185 hospitals and 2000 sites of
care, including surgery centers, urgent care
centers, emergency rooms, and physician
clinics in 21 states across the United States. All
collected data and patient information were
de-identified prior to analysis. Institutional
review board exemption was obtained after
review by the HCA Healthcare Institutional
Review Board manager system. Data collection
was conducted from January 2019 to February
2020.
We queried the HCA Healthcare electronic
admission, discharge, inpatient medication, and
billing records during the data collection period for all patients aged 18 to 65 years. Patients
included in the cohort required a diagnosis of
AUD (ICD 10 code F10 or ICD 9 code 303.90303.92). Data were limited to hospitalized patients. The corresponding medical records were
then used to extract demographic information,
discharge disposition, length of stay, and the
discharge medication list.

Measures

The independent variable was the presence of
the ACM on the discharge medication list following hospitalization. The ACMs were characterized as acamprosate or naltrexone appearing
on the discharge medication list at any dosage.
Discharge disposition, defined as whether the
patient was discharged home or referred to
a substance use treatment facility (STF), was
also reviewed as an intervention. Age, gender,
race, and insurance status were measured as
covariates. The primary outcome was whether or not the patient was readmitted within
30 and 90 days of discharge. The secondary
outcome was the blood alcohol concentration
measured on 30-day readmissions.

Statistical Analysis

Multivariate logistic regression was performed
to evaluate the association of ACM and the
likelihood of 30- and 90-day readmissions, as
both of the outcomes are binary. The odds
ratio (OR) was calculated from the logistic regression model. Linear regression was
performed to model the association of the
presence of ACM on discharge and BAC upon
30-day readmission. Controlled variables for all
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Table 1. Patient Characteristics
Total (N=14 691)

Received ACM (n=3308)

Did not
receive ACM (n=11 383)

n

%

n

%

n

%

Male

9953

67.7

2165

65.4

7788

68.4

Female

4738

32.3

1143

34.6

3595

31.6

White

11 195

76.2

2817

85.2

8378

73.6

Other

3496

23.8

491

14.8

3005

26.4

Uninsured

5407

36.8

1020

30.8

4387

38.5

Insured

9284

63.2

2288

69.2

6996

61.5

Sex

Race/ethnicity

Insurance type

regression models include age, sex (male versus
female), race (white versus non-white), and
insurance status (insured versus uninsured). A
generalized linear models procedure was used
to calculate the association of the aforementioned variables with BAC on 30-day readmission. All data were analyzed by SAS 9.4.

Results

Baseline characteristics including demographics are shown in Table 1. A total of 14 691 patients aged 18 to 65 years were admitted to an
HCA Healthcare hospital with the diagnosis
of AUD from January 2016 to December 2018.
The average age of patients sampled was 45.8
years. A total of 9953 (67.75%) patients were
male and 11 195 (76.2%) patients identified as
white. There were 5407 (36.8%) uninsured
patients. Table 2 shows discharge outcomes

of patients admitted with AUD. 3308 (22.52%)
patients were prescribed an ACM and 1125
(7.66%) patients were discharged to a STF.
There were 3448 (23.47%) patients readmitted
within 30 days while 5198 patients (35.38%)
were readmitted within 90 days.
Tables 3 and 4 show the results of multivariate
logistic regression models for 30-day and 90day readmissions. Patients discharged to a STF
were more likely to be readmitted within 30
days (OR = 1.57, 95% CI, 1.37-1.79; P < .0001). For
every 1-year increase in age, patients were more
likely to be readmitted within 30 days (OR =
1.013, 95% CI, 1.01-1.02; P < .0001). Non-white
patients were less likely to be readmitted within 30 days (OR = 0.85, 95% CI, 0.76-0.92; P =
.0002). Patients with insurance were more likely to be readmitted within 30 days (OR = 1.168,

Table 2. Discharge Outcomes
Total (N=14 691)

Received ACM (n=3308)

Did not
receive ACM (n=11 383)

n

%

n

%

n

%

Readmitted within 30 days
Yes

3448

23.5

709

21.4

2739

24.1

No

11 243

76.5

2599

78.6

8644

75.9

Readmitted within 90 days
Yes

5198

35.4

1173

35.5

4025

35.4

No

9493

64.6

2135

64.5

7358

64.6

Yes

1125

7.7

275

8.3

850

7.5

No

13 566

92.3

3033

91.7

10 533

92.5

Discharged to STF
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Table 3. Predictors of 30-day Readmissions
Variable

Odds ratio

95% confidence
intervals

P value

Female

0.785

0.720-0.855

< .0001

Discharged to rehab

1.569

1.376-1.795

< .0001

Insured

1.168

1.074-1.271

.0003

Non-white

0.835

0.760-0.918

.0002

No anti-craving home
medication

1.186

1.078-1.305

.0005

Age in years

1.013

1.010-1.016

< .0001

95% CI, 1.07-1.21; P = 0.0003). Females were less
likely to be admitted with 30 days (OR = 0.78,
95% CI, 0.72-0.85; P <0.0001).(Figure 1A)
ACMs did not have a significant relationship
with 90-day readmission rates. Patients discharged to STF were more likely to be readmitted within 90 days (OR = 1.29, 95% CI, 1.14-1.46;
P < .0001). For every increase of 1 year in age,
patients were more likely to be readmitted
within 90 days (OR = 1.014, 95% CI, 1.011-1.016;
P < .0001). Non-white patients were less likely
to be readmitted within 90 days (OR = 0.865,
95% CI, 0.796-0.939; P = .0005). Patients with
insurance were more likely to be readmitted
within 90 days (OR = 1.204, 95% CI, 1.117-1.296;
P < 00001). Females were less likely to be admitted within 90 days with an OR = 0.855 (95%
CI, 0.793-0.921; P < .0001). (Figure 1B)
ACM, age, and race did not have a significant
relationship with BAC on 30-day readmission.
While patients who were discharged home had
a lower likelihood of 30-day readmission, those
that were readmitted had a BAC 26.74 units
higher than that of readmitted patients who
were discharged to an STF (P = .041). Female
patients also had a BAC 22.89 units lower than

male patients at readmission (P = .0002). Although patients that were insured were more
likely to be readmitted, they had a BAC 34.13
units lower than uninsured patients at readmission (P < .0001). For every 1-day increase in the
length of stay, the BAC of readmitted patients
decreased by 5.11 units (P < .0001).

Discussion

A previous study showed that patients who
received ACM had decreased need for future
inpatient treatment.9 Patients who received
ACM in our study were less likely to be readmitted within 30 days than those who did not.
However, only 22.52% of the patients with AUD
received ACM. Our findings are consistent
with previous studies that show limited usage
of naltrexone and acamprosate in potential
treatment settings.5,8 Regional differences in
policies, as well as lack of familiarity with ACM
by general practitioners, may contribute to
the limited use of ACM. There is a statistically
significant association between the usage of
naltrexone or acamprosate and the reduction
of 30-day readmissions. While the association
may not be clinically significant, future studies should focus on proper dosages as well as

Table 4. Predictors of 90-day Readmissions
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Variable

Odds ratio

95% confidence
intervals

P value

Female

0.855

0.793-0.921

< .0001

Discharged to rehab

1.288

1.138-1.462

< .0001

Insured

1.204

1.117-1.296

< .0001

Non-white

0.865

0.796-0.939

.0005

No anti-craving home
medication

1.017

0.936-1.105

.6902

Age in years

1.014

1.011-1.016

< .0001
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A

B

30-Day Readmission Rate

90-Day Readmission Rate

Received
ACM
Discharged
to STF

Received
ACM
Discharged
to STF

White

White

Insured

Insured

Male

Male

0.0

0.5

1.0

1.5

2.0

0.0

Odds Ratio

0.5

1.0

1.5

2.0

Odds Ratio

Figure 1. Predictors for (A) 30- and (B) 90-day readmission rates.
long-term benefits of ACM to prevent alcohol
use relapse and further explore any potential
connection.
Sex, race, and insurance were all significant
predictors of readmission rates in patients
receiving ACM. A 1-year increase in age lacks
clinical significance since the odds ratio for 30day readmissions was close to 1. Future studies
should explore how age impact readmissions
for AUD. The elderly population is more likely
to have co-existing medical conditions, which
may be worsened by alcohol use. Elderly patients generally use more medications, which
may cause adverse reactions when mixed with
alcohol.12 Females with AUD were less likely to
be readmitted in 30 days compared to males.
This could be due to a number of factors such
as increased adherence to AUD treatment in
females, or males’ greater dependency on alcohol to relieve negative affective states. Males
have been shown to have higher rates of AUD
than females and generally consume alcohol in
greater quantities.13 We also found that nonwhites had lower readmission rates compared
to whites. Further exploration, including qualitative studies, needs to examine how sex and
race, as well as other social factors, may play a
role in AUD treatment outcomes.
Our study used the presence of insurance as a
marker to approximate financial status. Insured
patients were more likely to be readmitted
within 30 days. Insured patients were also
associated with a lower BAC, suggesting this
population may have greater motivation to be

readmitted once they relapse. This is attributed
to available resources and health support systems, although prospective clarifying research
is needed. Basu et al. have shown that in the
uninsured population there was a lower risk
of readmission in minority populations and an
increased risk among the white population,
compared to both racial groups with private
insurance.14 This is similar to our findings.
However, Basu et al. suggested that decreased
readmission rates are not necessarily a positive
outcome as that may be due to lack of access
to medical care or financial barriers.14
Only a small portion (7.66%) of patients in the
study were discharged to an STF. Patients discharged to a treatment facility were more likely
to be readmitted. It is likely due to the facility’s
ability to observe patients for criteria requiring
readmission as well as the patients’ own motivation to seek help for their AUD. This outcome
was further supported by findings that showed
patients discharged to STFs had lower BAC
upon 30-day readmission. STFs have the ability
to encourage adherence to ACM and also offer
therapy for alcohol use cessation. This finding
is supported by a previous study that demonstrated long-term abstinence after inpatient
rehabilitation.15 A higher BAC on readmission
for those not discharged to an STF suggests
that these patients came from an environment
that was unsupportive of their sobriety. Our
research indicated that ACM did not demonstrate a relationship with BAC on readmission.
However, the combination of ACM and discharge to STFs needs to be further explored as
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they may have a synergistic effect in reducing
the overall length of hospitalization in those
with AUD.

pretation and visualization of results, and the
initial draft of the manuscript.

There are several limitations of this study. First
is the lack of data on patient compliance with
ACM upon discharge. Despite this limitation,
the effects from short-term utilization of ACM
may persist beyond the treatment period.
Patients have shown positive results even after
discontinuing treatment with ACM.16 Second,
the study does not include disulfiram, which is
still used in some settings for some patients.
Third, the study does not specify whether rates
vary based on admission to a psychiatric bed
versus a general medical bed. The variables
presented may differ between the admission
units. Fourth, the study is not able to identify
why the use of ACM is relatively low, and
referral to STFs is lower yet. Prospective and
qualitative data would help to answer these
questions and further inform providers involved
in the care of patients with AUD. Our data were
limited specifically to HCA Healthcare hospitals.
Studying patients in non-HCA Healthcare
hospitals may reveal different results due to
factors such as the decision to treat with ACM
and the threshold for admission. Data on BAC
was limited to the difference in levels for each
demographic. Measuring average BAC levels
would help better understand the impact of
ACMs.

We would like to thank HCA Healthcare statistician Sarah Wilson as well as analyst Leslee
Keilty for their role in data collection and analysis. We would also like to thank Dr. Christopher
Ochner and Jocelyn Mineo for their role in the
submission process.

Conclusion

Our study indicates that patients who have
AUD and were discharged with ACM had decreased likelihood of being readmitted within
30 days. Although those discharged to STFs
were more likely to be readmitted within 30
days, they had lower BAC on readmission.
Education of best practices with providers
may increase the use of ACM and STFs. Future
studies should examine the long-term benefits
of ACM as well as the transfer of care to STFs
for the treatment of AUD.
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